Hopes f him him him rom Gilead news propel European shares higher. European indices are ending the session with solid gains on hopes from the Gilead remdesivir drug,
<p>John Flood, a partner at Goldman Sachs in a note to clients on Wednesday after the CPI data commented that </p><p>"For the 1st time in 2023, we are currently being asked by m
Leave a Comment